Literature DB >> 8993958

Double-blind crossover study of high-dose cetirizine in cholinergic urticaria.

T Zuberbier1, C Münzberger, U Haustein, E Trippas, B Burtin, S D Mariz, B M Henz.   

Abstract

BACKGROUND: Cholinergic urticaria does not respond well to treatment with conventional antihistamines and is difficult to study because of its highly variable clinical expression which depends on the presence of eliciting factors.
OBJECTIVE: We have therefore designed a double-blind, crossover, placebo-controlled trial, with a 3-week treatment period using either 20 mg/day of cetirizine or placebo. METHODS AND
RESULTS: Presence of eliciting factors and symptoms were scored daily on a diary card by the patient, with a scale from 0 to 3 for erythema, wheals and pruritus. Statistical analysis was done on 11 evaluable patients during the last 2 weeks of each treatment period (to allow for 1 week of washout) and only for days when eliciting factors were present. Compared to placebo, cetirizine caused a statistically significant reduction of wheals (p = 0.015), erythema (p = 0.033), pruritus (p = 0.006) and all symptoms (p = 0.013). No adverse events were observed.
CONCLUSION: These data show a high efficacy of cetirizine at twice its normally recommended dose which may be related to the specific antiallergic effects of this newer-generation antihistamine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8993958     DOI: 10.1159/000246281

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  21 in total

Review 1.  Current and future therapies for the treatment of histamine-induced angioedema.

Authors:  Christine James; Jonathan A Bernstein
Journal:  Expert Opin Pharmacother       Date:  2017-01-25       Impact factor: 3.889

Review 2.  Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management.

Authors:  Atsushi Fukunaga; Ken Washio; Mayumi Hatakeyama; Yoshiko Oda; Kanako Ogura; Tatsuya Horikawa; Chikako Nishigori
Journal:  Clin Auton Res       Date:  2017-04-05       Impact factor: 4.435

Review 3.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Idiopathic histaminergic angioedema without wheals: a case series of 31 patients.

Authors:  C Faisant; I Boccon-Gibod; C Mansard; C Dumestre Perard; P Pralong; C Chatain; A Deroux; L Bouillet
Journal:  Clin Exp Immunol       Date:  2016-04-13       Impact factor: 4.330

Review 5.  Skin manifestations of athletes competing in the summer olympics: what a sports medicine physician should know.

Authors:  Jacqueline F De Luca; Brian B Adams; Gil Yosipovitch
Journal:  Sports Med       Date:  2012-05-01       Impact factor: 11.136

Review 6.  [New therapeutic strategies for the different subtypes of urticaria].

Authors:  U Raap; T Liekenbröcker; D Wieczorek; A Kapp; B Wedi
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

Review 7.  Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy.

Authors:  Christian Vestergaard; Mette Deleuran
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

Review 8.  [Urticaria … and treatment fails].

Authors:  B Wedi; D Wieczorek; U Raap; A Kapp
Journal:  Hautarzt       Date:  2013-09       Impact factor: 0.751

9.  Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review.

Authors:  Gabriele Di Lorenzo; Alberto D'Alcamo; Manfredi Rizzo; Maria Stefania Leto-Barone; Claudia Lo Bianco; Vito Ditta; Donatella Politi; Francesco Castello; Ilenia Pepe; Gaetana Di Fede; Giovambattista Rini
Journal:  J Asthma Allergy       Date:  2008-12-09

10.  Challenges in the management of chronic urticaria.

Authors:  Todor A Popov
Journal:  World Allergy Organ J       Date:  2011-03       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.